JP6170933B2 - ペプチドの使用 - Google Patents

ペプチドの使用 Download PDF

Info

Publication number
JP6170933B2
JP6170933B2 JP2014540139A JP2014540139A JP6170933B2 JP 6170933 B2 JP6170933 B2 JP 6170933B2 JP 2014540139 A JP2014540139 A JP 2014540139A JP 2014540139 A JP2014540139 A JP 2014540139A JP 6170933 B2 JP6170933 B2 JP 6170933B2
Authority
JP
Japan
Prior art keywords
oral
sct
seq
administration
calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014540139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532722A5 (OSRAM
JP2014532722A (ja
Inventor
メータ，ノザー・エム
スターン，ウィリアム
スターマー，エイミー・エム
カルスダル，モルテン・アセル
ヘンリクセン，キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEYBIOSCIENCE SA
Original Assignee
KEYBIOSCIENCE SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEYBIOSCIENCE SA filed Critical KEYBIOSCIENCE SA
Publication of JP2014532722A publication Critical patent/JP2014532722A/ja
Publication of JP2014532722A5 publication Critical patent/JP2014532722A5/ja
Application granted granted Critical
Publication of JP6170933B2 publication Critical patent/JP6170933B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014540139A 2011-11-02 2012-11-02 ペプチドの使用 Expired - Fee Related JP6170933B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US61/554,771 2011-11-02
US201161578620P 2011-12-21 2011-12-21
US61/578,620 2011-12-21
US13/667,578 2012-11-02
PCT/US2012/063332 WO2013067357A1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders
US13/667,578 US9006172B2 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016216389A Division JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体

Publications (3)

Publication Number Publication Date
JP2014532722A JP2014532722A (ja) 2014-12-08
JP2014532722A5 JP2014532722A5 (OSRAM) 2015-11-26
JP6170933B2 true JP6170933B2 (ja) 2017-07-26

Family

ID=48192827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014540139A Expired - Fee Related JP6170933B2 (ja) 2011-11-02 2012-11-02 ペプチドの使用
JP2016216389A Expired - Fee Related JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体
JP2018081153A Expired - Fee Related JP6547034B2 (ja) 2011-11-02 2018-04-20 ペプチドの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016216389A Expired - Fee Related JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体
JP2018081153A Expired - Fee Related JP6547034B2 (ja) 2011-11-02 2018-04-20 ペプチドの使用

Country Status (10)

Country Link
US (1) US9006172B2 (OSRAM)
JP (3) JP6170933B2 (OSRAM)
KR (1) KR102019911B1 (OSRAM)
CN (1) CN103998052B (OSRAM)
AU (2) AU2012332265B2 (OSRAM)
BR (1) BR112014010701A2 (OSRAM)
CA (1) CA2854175A1 (OSRAM)
MX (1) MX351092B (OSRAM)
RU (1) RU2616511C2 (OSRAM)
WO (1) WO2013067357A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
JP6639389B2 (ja) * 2013-11-14 2020-02-05 キーバイオサイエンス・アクチエンゲゼルシャフト 疾患および障害を処置するためのカルシトニン模倣体
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
US11420525B2 (en) 2020-04-21 2022-08-23 Mac LTT, Inc. Tractor trailer with included battery charging
US11634095B2 (en) 2020-04-21 2023-04-25 Mac LTT, Inc. Removable safety bar for creating a remote safety visual device
US12415457B2 (en) 2020-04-21 2025-09-16 Mac LTT, Inc. Safety zone with breakaway for use on a tanker truck

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033478B2 (ja) * 1980-06-20 1985-08-02 帝国臓器製薬株式会社 ペプチドの製造方法
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4659804A (en) * 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
US4764589A (en) 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
JPH083196A (ja) 1994-06-21 1996-01-09 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン誘導体及びその用途
EP0726075A1 (en) 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
US5962270A (en) * 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6103495A (en) 1997-04-16 2000-08-15 Unigene Laboratories, Inc. Direct expression of peptides into culture media
CN1105726C (zh) * 1998-05-15 2003-04-16 中国科学院上海生物化学研究所 人降钙素类似物
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
JP2000290295A (ja) 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
GB0109438D0 (en) * 2001-04-17 2001-06-06 Isis Innovation Peptides
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
BRPI0412265A (pt) 2003-07-23 2006-09-05 Novartis Ag uso de calcitonina em osteoartrite
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2345113T3 (es) 2004-02-11 2010-09-15 Amylin Pharmaceuticals, Inc. Peptidos de la familia amilina y metodos para su obtencion y utilizacion.
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2007002532A2 (en) 2005-06-24 2007-01-04 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AU2010206614B2 (en) 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
CN102369018B (zh) * 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗

Also Published As

Publication number Publication date
AU2012332265A1 (en) 2014-06-05
KR102019911B1 (ko) 2019-09-09
NZ625215A (en) 2016-04-29
RU2014122171A (ru) 2015-12-10
JP2014532722A (ja) 2014-12-08
JP2017061500A (ja) 2017-03-30
AU2012332265B2 (en) 2016-11-10
CN103998052A (zh) 2014-08-20
WO2013067357A1 (en) 2013-05-10
AU2016247189B2 (en) 2017-09-14
KR20140093967A (ko) 2014-07-29
CN103998052B (zh) 2016-08-17
JP6330013B2 (ja) 2018-05-23
AU2016247189A1 (en) 2016-11-10
CA2854175A1 (en) 2013-05-10
BR112014010701A2 (pt) 2020-06-23
RU2616511C2 (ru) 2017-04-17
JP6547034B2 (ja) 2019-07-17
JP2018135360A (ja) 2018-08-30
US20130183385A1 (en) 2013-07-18
US9006172B2 (en) 2015-04-14
MX351092B (es) 2017-10-02
MX2014005265A (es) 2014-10-13

Similar Documents

Publication Publication Date Title
JP6170933B2 (ja) ペプチドの使用
JP6639389B2 (ja) 疾患および障害を処置するためのカルシトニン模倣体
JP2021535119A (ja) アシル化カルシトニン模倣体
US10239929B2 (en) Peptide analogs for treating diseases and disorders
JP2018502854A (ja) 疾患および障害を処置するためのカルシトニン類似体
DK3095484T3 (en) CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
JP2020511479A (ja) 疾患および障害を治療するためのカルシトニン模倣体
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2020039052A1 (en) Calcitonin mimetics for treating diseases and disorders
NZ625215B2 (en) Peptide analogs for treating diseases and disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170424

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170703

R150 Certificate of patent or registration of utility model

Ref document number: 6170933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees